The most common side effect of angiotensin-converting enzyme inhibitor (ACEi) drugs is
cough. We conducted a genome-wide association study (GWAS) of ACEi-induced cough …

Aim: We conducted a genome-wide association study on angiotensin-converting enzyme
inhibitor-induced cough and used our dataset to replicate candidate genes identified in …

Methods We carried out a monogenic association analysis of 39 polymorphisms and
haplotypes in genes encoding key proteins related to ACEi activity with the occurrence of …

Aim: Genetic polymorphisms may influence the incidence of angiotensin-converting enzyme
(ACE) inhibitor-induced cough. This study aims to investigate this association. Methods: Ten …

Methods A total of 281 patients who had been treated with ACEi were retrospectively
recruited [102 patients were considered as cases (cough) and 179 patients were considered …

Aims To search for sequence variants associated with ACEi discontinuation and to test their
association with ACEi-associated adverse drug reactions (ADRs). Methods and results A …

AIM: To evaluate the association between genetic polymorphisms and angiotensin
converting enzyme inhibitor (ACEI)-related cough, and the race-or ethnicity-related …

Objective An insertion/deletion (I/D) variant in the angiotensin-converting enzyme (ACE)
gene was associated with ACE inhibitor (ACEI)–related cough in previous studies. However …

Background: Angiotensin-converting enzyme (ACE) inhibitors-related cough had been
reported to contribute for discontinuation of ACE inhibitors therapy. The role of ACE I/D and …

Background and objective: Treatment with angiotensin‐converting enzyme (ACE) inhibitors
can induce chronic cough in many patients. Genetic variations in the neurokinin 2 receptor …